{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Jiang C"],"funding":["Shanghai Pudong Scientific and Technological development Projects","National Natural Science Foundation of China","National Key Research and Development Program of China"],"pagination":["275-286"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9816240"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["50(2)"],"pubmed_abstract":["Radionuclides theranostic are ideal \"partners\" for bispecific antibodies to explore the immune response of patients and synergistic treatment. A bispecific single-domain antibody-Fc fusion protein, KN046, exhibits a good treatment effect by binding to programmed cell death-ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). An ionizing-radiation stimulus mediated by a low-dose of [<sup>131</sup>I] may be used for immunopotentiation. In this study, we established [<sup>131</sup>I]-labeled KN046 as a novel radioimmunotherapy agent to treat malignant melanoma and explored the mechanism.<h4>Methods</h4>After intravenous injection of [<sup>131</sup>I]-KN046, SPECT/CT imaging was applied to identify candidate targets for KN046 immunotherapy. [<sup>18</sup>F]-FDG and [<sup>"],"journal":["European journal of nuclear medicine and molecular imaging"],"pubmed_title":["Enhanced antitumor immune responses via a new agent [<sup>131</sup>I]-labeled dual-target immunosuppressant."],"pmcid":["PMC9816240"],"funding_grant_id":["PKJ2020-Y55","81971648","2020YFA0909000"],"pubmed_authors":["He S","Yang Z","Chen J","Zhang J","Li P","Song S","Jiang C","Yao B","Xu X","Tian Q"],"additional_accession":[]},"is_claimable":false,"name":"Enhanced antitumor immune responses via a new agent [<sup>131</sup>I]-labeled dual-target immunosuppressant.","description":"Radionuclides theranostic are ideal \"partners\" for bispecific antibodies to explore the immune response of patients and synergistic treatment. A bispecific single-domain antibody-Fc fusion protein, KN046, exhibits a good treatment effect by binding to programmed cell death-ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). An ionizing-radiation stimulus mediated by a low-dose of [<sup>131</sup>I] may be used for immunopotentiation. In this study, we established [<sup>131</sup>I]-labeled KN046 as a novel radioimmunotherapy agent to treat malignant melanoma and explored the mechanism.<h4>Methods</h4>After intravenous injection of [<sup>131</sup>I]-KN046, SPECT/CT imaging was applied to identify candidate targets for KN046 immunotherapy. [<sup>18</sup>F]-FDG and [<sup>","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Jan","modification":"2025-04-21T16:16:21.983Z","creation":"2025-02-19T03:30:52.642Z"},"accession":"S-EPMC9816240","cross_references":{"pubmed":["36242616"],"doi":["10.1007/s00259-022-05986-4"]}}